G/MA/QR/N/CAN/4/Add.1  
 
17 December  2020 
(20-9126) Page: 1/3 
Committee on Market Access  Original: English  
 
  
NOTIFICATION PURSUANT TO THE DECISION ON NOTIFICATION  PROCEDURE S 
FOR QUANTITATIVE RESTRICTIONS (G/L/59/REV.1)  
CANADA  
Addendum  
The following communication, dated 15 December 2020 , is being circulated at the request of the 
delegation of Canada . 
 
A. Notifying Member :  Canada  
B. Date of notification :  15 December 2020  
C. First time notification:  
 Yes  
 No, last notification was made in (doc. symbol ): G/MA/QR/N/CAN/ 4 
D. Type of notification:  
 1. Complete (i.e. notification of all quantitative restrictions in force ) 
 2. Changes to a notification previously made in (doc symbol)  which are of the following 
nature : 
  2.1 Introduction of new restrictions, as listed in Section 1. 
  2.2 Elimination of restrictions, as described in G below . 
  2.3 Modification of a previously notified restriction, as described in Section 1. 
 3. Reverse notification of restrictions maintained by (Member ):  
E. The notification provides information for the follo wing biennial period 
(e.g.  2012 -2014): 2020-2022 and relates to restrictions in fo rce as of 26.11.2020 
F. This notification contains information* relating to:  
 Section  1: List of quantitative restrictions that are currently in force . 
 Section  2: Cross -reference to other WTO notifications with information on quantitative 
restrictions that are currently in force and additional information . 
G. Comments of a general nature, including a description of the elimination of 
restrictions notified under D.2.2 and the date they ceased t o be in force.  
Canada is notifying a measure that was adopted to prevent critical shortages of its 
pharmaceutical drug supply.  
 
 
* In English  only.  
  G/MA/QR/N/CAN/4/Add.1  
 
- 2 - Section 1: List of quantitative restrictions that are currently in force  
 
QR 
No. General 
description of 
the restriction  Type of 
restriction  
 Tariff line code(s) 
affected, based on 
HS(2017 ) Detailed 
Product 
Description  WTO Justification  
and Ground for 
Restriction, e.g. 
Other International 
Commitments  National legal 
basis and entry 
into force   
 Administration, modification of 
previously notified measures, 
and other comments  
 1 2 3 4 5 6 7 
1 Conditional 
prohibition of 
the export of 
certain 
pharmaceuticals   CP - X Various products under 
HS Chapters 29 and 30  
 
Products include:  
 
1. Drugs included in 
Schedule I, II, III, IV or 
V to the Controlled 
Drugs and Substances 
Act; 
EN  https://laws -
lois.justice.gc.ca/eng/a
cts/c-38.8/   
 
FR  https://laws -
lois.justice.gc.ca/fra/loi
s/c-38.8/   
 
2. Prescription drugs,  
as defined in section 
A.01.010 of the Food 
and Drug Regulations;  
EN  https://laws -
lois.justice.gc.ca/eng/re
gulations/c.r.c.%2C_c.
_870/index.html   
FR  https://laws -
lois.justice.gc.ca/fra/re
glements/C.R.C.%2C_c
h._870/index.html   
 
3. Drugs that are listed 
in Schedule C or D to 
the Food and Drugs 
Act; and  Pharmaceuticals  Article XI:2(a) of 
the GATT  
 Interim Order 
Respecting Drug 
Shortages 
(Safeguarding the 
Drug Supply)  
 
Entry into force on 
26.11.2020  
 
Arrêté d’urgence 
sur les pénuries 
de drogues 
(protection de 
l’approvisionneme
nt en drogues)  
 
Entrée en vigueur 
le 26.11.2020  The Interim Order does not prohibit 
exports but provides the Minister of 
Health the authority to do so if a 
sale would cause or exacerbate a 
critical drug shortage.  
 
Interim Order  Respecting Drug 
Shortages (Safeguarding the Drug 
Supply)  
https://www.canada.ca/en/health -
canada/services/drugs -health -
products/com pliance -
enforcement/importation -
exportation/interim -order -drug-
shortages -protecting -supply.html   
 
Explanatory note  
https://www.canada.ca/en/health -
canada/services/drugs -health -
products/compliance -
enforcement/importation -
exportation/interim -order -drug-
shortages -protecting -
supply/note.html   
 
Arrêté d’urgence  sur les pénuri es 
de drogues (protection de 
l’approvisionnement en drogues)  
https://www.canada.ca/fr/sante -
canada/services/medicaments -
produits -sante/conformite -
application -loi/importation -
exportation/arrete -urgence - 
  G/MA/QR/N/CAN/4/Add.1  
 
- 3 - QR 
No. General 
description of 
the restriction  Type of 
restriction  
 Tariff line code(s) 
affected, based on 
HS(2017 ) Detailed 
Product 
Description  WTO Justification  
and Ground for 
Restriction, e.g. 
Other International 
Commitments  National legal 
basis and entry 
into force   
 Administration, modification of 
previously notified measures, 
and other comments  
 1 2 3 4 5 6 7 
EN  https://laws -
lois.justice .gc.ca/eng/a
cts/f-27/  
FR  https://laws -
lois.justice.gc.ca/fra/loi
s/f-27/  
 
4. Drugs that are 
permitted to be sold 
without a prescription, 
as defined in subsection 
C.01.001(1) of the 
Food and D rug 
Regulations, but that 
are to be administered 
only under the 
supervision of a 
practitioner, as defined 
in that subsection.  
EN  https://laws -
lois.justice.gc.ca/en g/re
gulations/c.r.c.%2C_c.
_870/index.html   
FR  https://laws -
lois.justice.gc.ca/fra/re
glements/C.R.C.%2C_c
h._870/index.html   penuries -drogues -protection -
approvisionnement.html   
 
 
Note explicative  
https://www.canada.ca/fr/sante -
canada/services /medicaments -
produits -sante/conformite -
application -loi/importation -
exportation/arrete -urgence -
penuries -drogues -protection -
approvisionnement/note.html   
 
__________